Compositions ameliorating a reduced diurnal activity and/or depressive symptoms
A composition having an activity of ameliorating the reduced amount of diurnal activity and/or depressive symptoms, comprising arachidonic acid and/or a compound having arachidonic acid as a constituent fatty acid.
1. A method of treating depression resulting from sleep disorders that are caused by a mental disease or a neurological disease, comprising administering an effective amount of a composition to a human subject having the depression, wherein the composition comprises arachidonic acid and/or a compound having arachidonic acid as a constituent fatty acid, wherein the effective amount of the composition includes 240 mg of arachidonic acid per day.
2. The method of claim 1 , wherein the compound having arachidonic acid as a constituent fatty acid is an alcohol ester of arachidonic acid or a triglyceride, a phospholipid, or a glycolipid in which part or all of the constituent fatty acid is arachidonic acid.
3. The method of claim 2 , wherein the triglyceride in which part or all of the constituent fatty acid is arachidonic acid is a triglyceride in which a middle-chain fatty acid is bound at positions 1 and 3 and arachidonic acid is bound at position 2, wherein the middle-chain fatty acid is one selected from fatty acids having 6-12 carbons.
4. The method of claim 1 , wherein the composition comprises triglycerides that contain a triglyceride in which part or all of the constituent fatty acid is arachidonic acid.
5. The method of claim 4 , wherein the ratio of arachidonic acid in the triglycerides that contain a triglyceride in which part or all of the constituent fatty acid is arachidonic acid is 10% by weight or more relative to the total fatty acids constituting the triglycerides.
6. The method of claim 4 , wherein the triglycerides that contain a triglyceride in which part or all of the constituent fatty acid is arachidonic acid are extracted from a microorganism belonging to genus Mortierella , genus Conidiobolus , genus Pythium , genus Phytophthora , genus Penicillium , genus Cladosporium , genus Mucor , genus Fusarium , genus Aspergillus , genus Rhodotorula , genus Entomophthora , genus Echinosporangium and genus Saprolegnia.
7. The method of claim 4 , wherein the triglycerides that contain a triglyceride in which part or all of the constituent fatty acid is arachidonic acid are triglycerides containing eicosapentaenoic acid at an amount not exceeding one fifth (weight ratio) of arachidonic acid.
8. The method of claim 1 , wherein the composition comprises triglycerides that contain 5 mole % or more of a triglyceride in which a middle-chain fatty acid is bound at positions 1 and 3 and arachidonic acid is bound at position 2, wherein the middle-chain fatty acid is one selected from fatty acids having 6-12 carbons.
9. The method of claim 1 , wherein the mental disease is schizophrenia or depression.
10. The method of claim 1 , wherein the neurological disease is cerebral degenerative diseases, dementia, or Parkinson's disease.
11. The method of claim 1 , wherein the composition is a food composition or a pharmaceutical composition.
12. The method of claim 11 , wherein the food composition is a functional food, nutrient supplement, modified milk for premature infants, modified milk for babies, baby food, food for pregnant women, or food for elderly people.
13. The method of claim 1 , wherein the composition further comprises docosahexaenoic acid or a compound having docosahexaenoic acid as a constituent fatty acid.
14. The method of claim 13 , wherein the compound having docosahexaenoic acid as a constituent fatty acid is an alcohol ester of docosahexaenoic acid or a triglyceride, a phospholipid or a glycolipid in which part or all of the constituent fatty acid is docosahexaenoic acid.
15. The method of claim 13 , wherein the weight ratio of arachidonic acid/docosahexaenoic acid in the combination of said arachidonic acid and said docosahexaenoic acid is in the range of 0.1-15.